Therapeutic Options for Metastatic Breast Cancer

Adv Exp Med Biol. 2019:1152:131-172. doi: 10.1007/978-3-030-20301-6_8.

Abstract

Metastatic breast cancer is the most common cancer in women after skin cancer, with a 5-year survival rate of 26%. Due to its high prevalence, it is important to develop therapies that go beyond those that just provide palliation of symptoms. Currently, there are several types of therapies available to help treat breast cancer including: hormone therapy, immunotherapy, and chemotherapy, with each one depending on both the location of metastases and morphological characteristics. Although technological and scientific advancements continue to pave the way for improved therapies that adopt a targeted and personalized approach, the fact remains that the outcomes of current first-line therapies have not significantly improved over the last decade. In this chapter, we review the current understanding of the pathology of metastatic breast cancer before thoroughly discussing local and systemic therapies that are administered to patients diagnosed with metastatic breast cancer. In addition, our review will also elaborate on the genetic profile that is characteristic of breast cancer as well as the local tumor microenvironment that shapes and promotes tumor growth and cancer progression. Lastly, we will present promising novel therapies being developed for the treatment of this disease.

Keywords: Drug delivery systems; Immunotherapy; Metastatic breast cancer; Nanoparticles; Oseltamivir phosphate; Targeted therapies; Tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / therapy*
  • Female
  • Humans
  • Immunotherapy
  • Neoplasm Metastasis / therapy*
  • Tumor Microenvironment

Substances

  • Antineoplastic Agents